What is Cyteir Therapeutics Financial Strength?
Cyteir Therapeutics has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Cyteir Therapeutics Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Cyteir Therapeutics has no long-term debt (1).
As of today, Cyteir Therapeutics's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Cyteir Therapeutics's Financial Strength
For the Biotechnology subindustry, Cyteir Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyteir Therapeutics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Cyteir Therapeutics's Financial Strength falls into.
Cyteir Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Cyteir Therapeutics's Interest Expense for the
months ended in Sep. 2023 was $0.00 Mil. Its Operating Income for the
months ended in Sep. 2023 was $-5.17 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil.
Cyteir Therapeutics's Interest Coverage for the quarter that ended in Sep. 2023 is
| Cyteir Therapeutics had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Cyteir Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Cyteir Therapeutics's Debt to Revenue Ratio for the quarter that ended in Sep. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Cyteir Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyteir Therapeutics (Cyteir Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
128 Spring Street, Building A, Suite 510, Lexington, MA, USA, 02421
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
Executives
| Novo Holdings A/s |
10 percent owner |
TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
| Joseph S Zakrzewski |
director |
509 WATERVIEW PLACE, NEW HOPE PA 18938 |
| John F Thero |
director |
C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921 |
| Adam M Veness |
officer: General Counsel |
C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036 |
| Stephen H. Sands |
director |
128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
| Jeffrey Humphrey |
director |
C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142 |
| Droia Invest Ii Scsp |
10 percent owner |
28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
| Janwillem Naesens |
director |
128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
| Sa Ihl |
10 percent owner |
28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
| Karen Hong |
director |
69 PARKSIDE DRIVE, PRINCETON NJ 08540 |
| Bv Wepaven |
10 percent owner |
BRUSSELSESTEENWEG 11, MEISE C9 1860 |
| Luc Verelst |
10 percent owner |
28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
| Df Ii Gp Sarl |
10 percent owner |
28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
| Timothy Romberger |
director |
128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
| Racquel Bracken |
director |
128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
Cyteir Therapeutics (Cyteir Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYTT has been successfully added to your